US Patent

US8343952 — Prolyl hydroxylase inhibitors and methods of use

Composition of Matter · Assigned to Akebia Therapeutics Inc · Expires 2027-08-14 · 1y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a class of compounds, specifically HIF-1α prolyl hydroxylase inhibitors, used to treat various conditions including Peripheral Vascular Disease and heart failure.

USPTO Abstract

The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.

Drugs covered by this patent

Patent Metadata

Patent number
US8343952
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-08-14
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Akebia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.